Health Groups Demand Andy Burnham Scrap 'Deadly' UK-US Pharmaceutical Trade Deal

Health Groups Pressure Burnham to Abandon UK-US Pharma Agreement

Andy Burnham is facing mounting pressure from doctors and health campaigners to tear up the controversial UK-US pharmaceutical trade deal, with warnings that the agreement places drug company profits far above the wellbeing of NHS patients.

The deal, signed in December of last year, has been defended by ministers as a mechanism to shield British medicine exports from American tariffs while expanding patient access to potentially life-saving treatments. However, critics argue that the agreement amounts to a capitulation to pressure from Donald Trump's administration — one that will force the NHS to spend billions more annually on US-supplied drugs.

What the Analysis Reveals

A damning assessment by academics from the University of York, the University of Liverpool, and Christchurch Hospital in New Zealand paints a stark picture of the deal's consequences. According to their findings, the agreement would divert approximately £44.7 billion away from NHS health services by 2036 in order to cover inflated drug costs — unless the government provides substantial additional funding to offset those expenses.

The knock-on effect of such a dramatic reduction in NHS service spending, researchers warn, could result in 229,000 excess deaths over that same period. This figure follows a Guardian report last week revealing that the NHS would need to redirect £45 billion from essential care in order to meet its new financial obligations under the deal.

A Letter Demanding Change

In a coordinated letter seen by the Guardian, 19 prominent health organisations have written directly to Burnham — widely expected to succeed Keir Starmer as Labour leader and Prime Minister within weeks — urging him to scrap the agreement entirely.

The letter, coordinated by the SOS NHS coalition, calls on Burnham to make a "decisive break" with current policy and dedicate his leadership to rebuilding the health service from the ground up. Signatories include Medact, the Doctors' Association UK, and Doctors in Unite, who also raise concerns about Private Finance Initiative arrangements at neighbourhood health centres, recent NHS workforce reductions, the growing role of private healthcare providers, and Palantir's controversial NHS data contract.

Voices From the Front Lines

Dr Tony O'Sullivan, co-chair of Keep Our NHS Public and a retired consultant paediatrician, was unsparing in his criticism of the deal.

"Donald Trump's demands for higher drug prices are set to drain an estimated £45 billion from the NHS over the next decade," he said. "At a time when patients are waiting longer than ever for treatment, handing over billions more to US pharmaceutical giants is like trying to put out a fire while pouring petrol on the flames."

Dr O'Sullivan highlighted the NHS's already fragile state, noting that approximately 16,000 people die unnecessarily each year due to delays in emergency care, while millions remain stranded on waiting lists. He called on Burnham to meet with healthcare campaigners and those with frontline NHS experience, describing the leadership transition as a crucial opportunity to reverse policies that have consistently placed corporate interests over patient welfare.

Hope Worsdale of patient advocacy group Just Treatment was equally forceful in her condemnation, describing the deal as signed "to inflate drug company profits" and calling it a profound betrayal of both the NHS and the British public.

"Andy Burnham has said this is the last chance to save the Labour party," Worsdale said. "It is also the last chance to save the NHS. As prime minister, he must deliver the life-saving investment his predecessors failed to prioritise, scrap the dangerous pharma deal, and stop private companies ripping off our NHS."

Burnham's Record and His Silence

Despite the mounting calls for action, Burnham has not publicly responded to questions about whether he intends to challenge or dismantle the UK-US trade agreement.

His NHS track record is mixed. When he last served as Health Secretary following 2009, Burnham made headlines by declaring the NHS the "preferred provider" of NHS care — a bold move intended to push back against accelerating privatisation. Yet a year later, he approved a PFI deal for the Royal Liverpool Hospital, managed by facilities company Carillion. The project ran years behind schedule and exceeded its original budget by £300 million before Carillion collapsed into liquidation.

A Defining Moment for the NHS

With Burnham poised to take the reins of government, health organisations across the country are watching closely. For campaigners, the stakes could not be higher — they view the scrapping of this pharmaceutical agreement not merely as a policy decision, but as a defining test of whether a Burnham-led government will genuinely champion the NHS or allow it to be quietly dismantled by commercial and international pressures.